These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15542190)

  • 1. Epidermal powder immunization against influenza.
    Dean HJ; Chen D
    Vaccine; 2004 Dec; 23(5):681-6. PubMed ID: 15542190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal DNA vaccine for influenza is immunogenic in humans.
    Drape RJ; Macklin MD; Barr LJ; Jones S; Haynes JR; Dean HJ
    Vaccine; 2006 May; 24(21):4475-81. PubMed ID: 16150518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity.
    Chen D; Burger M; Chu Q; Endres R; Zuleger C; Dean H; Payne LG
    Virus Res; 2004 Jul; 103(1-2):147-53. PubMed ID: 15163503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
    Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
    Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia.
    Morales A; Arias Salazar J; Salazar Y; García A; Arnoux S; Arancibia A; Deroche C; Rey E
    Medicina (B Aires); 2003; 63(3):197-204. PubMed ID: 12876902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial.
    Chiu SS; Chan KH; Tu W; Lau YL; Peiris JS
    Vaccine; 2009 Jul; 27(35):4834-9. PubMed ID: 19523908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
    Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
    J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with humoral primary immunodeficiency do not develop protective anti-influenza antibody titers after vaccination with trivalent subunit influenza vaccine.
    van Assen S; Holvast A; Telgt DS; Benne CA; de Haan A; Westra J; Kallenberg CG; Bijl M
    Clin Immunol; 2010 Aug; 136(2):228-35. PubMed ID: 20421178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F; Vaman T; Kafeja F; Hanon E; Van Damme P
    Clin Infect Dis; 2010 Sep; 51(6):668-77. PubMed ID: 20687838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice.
    Amorij JP; Saluja V; Petersen AH; Hinrichs WL; Huckriede A; Frijlink HW
    Vaccine; 2007 Dec; 25(52):8707-17. PubMed ID: 17996993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
    Del Porto F; Laganà B; Biselli R; Donatelli I; Campitelli L; Nisini R; Cardelli P; Rossi F; D'Amelio R
    Vaccine; 2006 Apr; 24(16):3217-23. PubMed ID: 16466833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity.
    Lu CC; Wang YC; Lai JH; Lee TS; Lin HT; Chang DM
    Vaccine; 2011 Jan; 29(3):444-50. PubMed ID: 21078406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.